8-K: Glaukos Reports Record Q4 Sales, Reaffirms 2024 Revenue Guidance

Glaukos Corporation announced record fourth-quarter net sales of $82.4 million, a 16% increase year-over-year, and reaffirmed its 2024 revenue guidance of $350 to $360 million.

Summary

• Glaukos Corporation reported record net sales of $82.4 million for the fourth quarter of 2023, representing a 16% increase year-over-year on a reported basis and 15% on a constant currency basis.
• Glaucoma net sales reached $60.6 million in Q4 2023, a 15% increase year-over-year, while Corneal Health net sales were $21.8 million, up 19% year-over-year.
• The company's gross margin was approximately 77% in Q4 2023, with a non-GAAP gross margin of approximately 84%.
• For the full year 2023, net sales totaled $314.7 million, an 11% increase year-over-year on a reported basis and 12% on a constant currency basis.
• Glaukos reaffirmed its 2024 net sales guidance of $350 million to $360 million.
• The company's non-GAAP loss from operations in Q4 2023 was $32.4 million, compared to a non-GAAP operating loss of $27.4 million in Q4 2022.
• Non-GAAP net loss for Q4 2023 was $30.6 million, or ($0.63) per diluted share, compared to a non-GAAP net loss of $25.1 million, or ($0.53) per diluted share, in Q4 2022.
• The company ended the fourth quarter of 2023 with approximately $301 million in cash and cash equivalents, short-term investments, and restricted cash.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and reaffirmed guidance, but also acknowledges increased expenses and losses. The company's pipeline progress and strategic investments are encouraging, but the financial losses and risks temper the overall sentiment.

Positives

• Record net sales were achieved in Q4 2023, demonstrating strong growth.
• Both Glaucoma and Corneal Health segments showed significant year-over-year revenue increases.
• The company maintained a strong non-GAAP gross margin of approximately 84% in Q4 2023.
• Glaukos has a robust pipeline with multiple ongoing clinical trials and recent FDA approval for iDose TR.
• The company has a strong cash position of approximately $301 million.
• International Glaucoma sales showed strong growth, indicating successful expansion efforts.
• The company is focused on expanding access for keratoconus patients with its Photrexa therapy.

Negatives

• The company experienced a loss from operations in both Q4 2023 and the full year 2023.
• Non-GAAP operating loss increased in Q4 2023 compared to Q4 2022.
• SG&A expenses increased significantly in both Q4 2023 and the full year 2023.
• The company's net loss per share increased in both Q4 2023 and the full year 2023 compared to the previous year.
• There is potential ordering pattern volatility within the U.S. Glaucoma franchise due to uncertainty associated with MAC LCDs.
• The company faces continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery.

Risks

• The company faces risks related to the impact of macroeconomic conditions, including foreign currency fluctuations.
• There are risks associated with reduced physician fee and ASC facility fee reimbursement rates for procedures utilizing the company's iStent products.
• The company depends on a limited number of third-party suppliers, some of which are single-source.
• There are risks related to securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the company's products.
• The company faces competition in the medical device industry, including from current and future MIGS technologies.
• There are risks associated with the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from regulatory approval processes.
• The company faces risks of recalls or serious safety issues with its products and the uncertainty of patient outcomes.
• There are risks related to protecting the company's intellectual property against third parties and competitors.

Future Outlook

Glaukos expects 2024 net sales to be in the range of $350 million to $360 million, with potential contributions from iStent infinite and iDose TR, and anticipates some volatility in the U.S. Glaucoma franchise due to MAC LCD uncertainties.

Management Comments

• Thomas Burns, Glaukos chairman and chief executive officer, stated that the record fourth quarter results cap off a successful year of global execution and key milestone achievements.
• Mr. Burns also mentioned that the company is well positioned to execute its strategic plans and believes the coming years will be transformative.
• Management believes the company's platforms and product candidates have the ability to generate a robust cadence of new product introductions over the coming years that can generate layers of future growth.

Industry Context

Glaukos is a key player in the ophthalmic medical technology industry, particularly in the development of Micro-Invasive Glaucoma Surgery (MIGS) devices. The company's focus on novel, dropless therapies aligns with the industry's trend towards less invasive and more patient-friendly treatment options. The company's expansion into corneal and retinal diseases also reflects a broader trend of companies diversifying their portfolios to address multiple eye conditions.

Comparison to Industry Standards

• Glaukos's 16% year-over-year revenue growth in Q4 2023 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• Companies like Alcon and Johnson & Johnson Vision, which also operate in the ophthalmic space, have reported similar growth in certain segments but Glaukos's focus on MIGS and novel therapies gives it a unique position.
• The company's non-GAAP gross margin of 84% is competitive with other medical device companies that have a strong focus on proprietary technology and high-value products.
• Compared to companies like Ivantis (with whom Glaukos had a patent litigation settlement), Glaukos has a broader product portfolio and a more established market presence in MIGS.
• The company's investment in R&D, with over $500 million since 2018, is significant and indicates a commitment to innovation, which is crucial for maintaining a competitive edge in the medical device industry.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, pipeline progress, and future guidance.
• Employees will be affected by the company's growth and strategic initiatives.
• Customers (ophthalmic surgeons and patients) will benefit from the company's innovative products and therapies.
• Suppliers will be impacted by the company's demand for components and materials.
• Creditors will be impacted by the company's financial health and ability to service its debt.

Next Steps

• The company will continue the commercial launch of iDose TR.
• Glaukos will advance the PMA pivotal trial for iStent infinite.
• The company will progress the clinical development program for Retina XR (GLK-401).
• Glaukos will continue the Phase 2a clinical trial for iLution Travoprost.
• The company will work towards trial completion in the second Phase 3 confirmatory pivotal trial for Epioxa, with a targeted NDA submission by the end of 2024.
• Glaukos will prepare to commence a Phase 3 clinical trial for iDose TREX by the end of 2024.

Key Dates

Keywords

Glaukos, ophthalmic, glaucoma, corneal health, retinal disease, MIGS, iStent, iDose TR, Photrexa, revenue, clinical trials, medical technology, pharmaceuticals